Moreover, the trend toward personalized medicine is adding additional complexity to API intermediate development. As the pharmaceutical industry moves toward more targeted therapies, the need for custom intermediates that fit specific patient needs is increasing, thereby adding further demands on production processes.
The challenges associated with the degradation of perfluorinated compounds have spurred significant research aimed at developing safer alternatives and remediation strategies. Advances in green chemistry may allow for the synthesis of fluorinated compounds that break down more easily in the environment, thereby balancing utility with ecological responsibility.